Lupin Ltd. Sees Significant Block Trade on NSE Amidst ESG Rating Update
Lupin Ltd. experienced a significant block trade on the NSE, with 302,321 shares changing hands at Rs. 1,886.80 per share, totaling Rs. 57.04 crores. The company also received an ESG rating of '62' for FY24 from NSE Sustainability Ratings & Analytics Limited, based on publicly available data. Lupin disclosed this rating in compliance with SEBI regulations.

*this image is generated using AI for illustrative purposes only.
Block Trade Highlights Investor Interest
Lupin Ltd. , a prominent player in the pharmaceutical sector, witnessed a substantial block trade on the National Stock Exchange (NSE) recently. Approximately 302,321 shares of the company changed hands in a single transaction, valued at Rs. 57.04 crores. The trade was executed at a price of Rs. 1,886.80 per share, reflecting current market valuation for the pharmaceutical giant.
ESG Rating Assigned
In a separate development, Lupin Limited has received an Environmental, Social, and Governance (ESG) rating of '62' for the fiscal year 2024. This rating was independently assigned by NSE Sustainability Ratings & Analytics Limited, based on publicly available data pertaining to FY24.
Corporate Governance and Transparency
The company, in line with its commitment to transparency and regulatory compliance, disclosed this ESG rating through a filing under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited, signed off on this disclosure.
Market Implications
The occurrence of a significant block trade, coupled with the assignment of an ESG rating, may signal ongoing investor interest in Lupin Ltd. Block trades of this magnitude are often indicative of institutional activity and can sometimes influence market sentiment.
While the ESG rating provides insight into the company's performance on environmental, social, and governance factors, it's worth noting that Lupin did not engage NSE Sustainability for this rating. Instead, it was prepared independently based on publicly available information.
As the pharmaceutical sector continues to be a focus of investor attention, developments such as these at Lupin Ltd. underscore the importance of both financial transactions and non-financial metrics in shaping market perceptions.
Investors and market watchers will likely keep a close eye on Lupin's stock performance and future disclosures to gauge the impact of these events on the company's market position and stakeholder confidence.
Historical Stock Returns for Lupin
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
-1.08% | +2.10% | -1.00% | -9.21% | +6.45% | +123.84% |